## Drug Summary
Thioguanosine diphosphate (thio-GDP) is not a commonly recognized drug entity but appears to be a biochemical derivative relating to guanosine diphosphate (GDP) analogs. Since there is no widely recognized therapeutic application under this name, it may potentially be a research chemical or intermediate involved in biochemical pathways or pharmaceutical synthesis. Guanosine diphosphate itself is a nucleotide involved in many intracellular processes, including signal transduction and the synthesis of glycoproteins. If thioguanosine diphosphate is indeed utilized therapeutically, its mechanism could be similar to other nucleotide analogs, often involving the disruption of nucleic acid synthesis or function.

## Drug Targets, Enzymes, Transporters, and Carriers
Without specific information provided for thioguanosine diphosphate and a lack of broad recognition in pharmacological contexts, it's challenging to specify particular targets, enzymes, transporters, or carriers directly associated with this compound. Typically, nucleotide analogs might interact with enzymes involved in nucleotide metabolism, such as kinases, polymerases, or phosphatases. These interactions usually depend on the structural similarity of the analog to the naturally occurring nucleotide.

## Pharmacogenetics
There is no specific pharmacogenetic information available for thioguanosine diphosphate given its obscure status. For nucleotide analogs in general, pharmacogenetic responses can often be influenced by genetic variations in the genes coding for enzymes responsible for the metabolism of these compounds. For instance, polymorphisms in kinases, nucleotide transporters, and other metabolizing enzymes could potentially alter the efficacy and safety profile of such treatments. Without direct study or clinical use evidence, any pharmacogenetic associations for thioguanosine diphosphate are purely speculative.